Shared decision-making and structured follow-ups have been shown to improve adherence and patient satisfaction, with supervised programs achieving 65% higher adherence than self-monitoring approaches [1] Access to health coaching or behavior support tools, since GLP-1 receptor agonists combined with lifestyle modification produce a mean weight loss of 7.13 kg vs control in pooled trials, with additional cardiometabolic improvements [2] Transparent pricing with no hidden fees, no decoy intro promos, and no membership traps Reliable access to compounded GLP-1s through a publicly named 503A pharmacy partner, with the additive (B12, glycine, no additive) disclosed Cold-chain medication shipping with tracking, plus all required injection supplies in the box A secure, user-friendly digital platform with a real cancel button (not one that routes to a phone call) For compounded semaglutide specifically, prefer providers that name their pharmacy partners publicly and disclose disciplinary history

Greig, he's from NIH or from NIA, I can't remember, right
These systems require upfront capital spending, but they can generate long-term cost savings by reducing the need for fresh solvent deliveries and minimizing hazardous waste volumes
10.2337/dc17-1902 10
Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind